Skip to main content
. 2023 Dec 1;21:378. doi: 10.1186/s12957-023-03253-w

Table 2.

Gene alteration status (patients, N = 35)

KRAS mutation
 Mutation 10 (28.6%)
 Wild type 18 (51.4%)
 N/A 7 (20.0%)
NRAS mutation
 Mutation 2 (5.7%)
 Wild type 17 (48.6%)
 N/A 16 (45.7%)
BRAF mutation
 Mutation 3 (8.6%)
 Wild type 27 (77.1%)
 N/A 5 (14.3%)
HER2 overexpression
 Positive 0 (0%)
 Negative 10 (28.6%)
 N/A 25 (71.4%)
MSI (microsatellite instability)
 MSI-high 0 (0%)
 MSI-low 21 (60.0%)
 MSS (microsatellite stable) 0 (0%)
 N/A 14 (40.0%)
UGT1A1
 TA6/TA6 13 (37.1%)
 TA6/TA7 4 (11.4%)
 TA7/TA7 1 (2.9%)
 N/A 17 (48.6%)